WHEAT BRAN FIBER EFFECT ON ADENOMATOUS POLYP RECURRENCE
麦麸纤维对腺瘤性息肉复发的影响
基本信息
- 批准号:6236786
- 负责人:
- 金额:$ 36.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-03-01 至 1998-02-28
- 项目状态:已结题
- 来源:
- 关键词:adenomatous polyps biomarker biopsy bone density cancer prevention cancer risk clinical trials colorectal neoplasms deoxycholate dietary fiber dietary supplements endoscopy feces analysis human subject human therapy evaluation intestinal mucosa longitudinal human study neoplasm /cancer nutrition therapy neoplasm /cancer relapse /recurrence nutrition aspect of cancer nutrition related tag preneoplastic state proliferating cell nuclear antigen protein kinase C therapy compliance
项目摘要
Colorectal cancer continues as the second leading cause of cancer death
in the United States with 53,000 deaths in 1993. There is continuing
controversy concerning the potential role of dietary fiber in the
prevention of colon cancer. The results of animal studies, human
epidemiologic studies, and mechanisms of action evaluations strongly
suggest an inverse relationship between wheat bran fiber intake and
colon adenoma and cancer incidence. Furthermore, high intakes of wheat
bran fiber in both experimental carcinogenesis animal models and human
metabolic epidemiology studies has been associated with significant
reductions in fecal secondary bile acids, especially deoxycholic acid
which is a well documented colon tumor promoting agent. Results of two
relatively small, randomized Phase III intervention studies have been
published. De Cosse et al. found that fiber supplementation in excess
of 11 gm/day reduced the incidence of polyp recurrence in their study
of 58 patients with familial adenomatous polyposis. A preliminary
analysis of a study by Macrae and MacLennan in 400 patients with
resected adenomatous polyps suggested that wheat bran fiber
supplementation is associated with a significant reduction in recurrent
adenoma size and degree of dysplasia. In our previous study of wheat
bran fiber and calcium supplementation in 100 patients with resected
colonic polyps we found high dose wheat bran fiber (13.5 gm/d)
significantly reduced fecal total, primary, and secondary (including
deoxycholic acid) bile acid concentrations and excretion rates at 9
months of supplementation as compared to baseline and 3 month levels.
Our current, double-blind, placebo controlled Phase III cancer control
study has been designed to measure the effects of wheat bran fiber
supplementation (13.5 gm/d vs 2.0 gm/d X 3 years) on adenoma recurrence
(at the year one and three year colonoscopies), epithelial cell
proliferation (as measured by proliferating cell nuclear antigen or PCNA
Labeling Index), fecal and plasma bile acid concentrations, and protein
kinase C isotype expression and enzyme activity. To date more than 1550
patients with a history of a resected adenomatous polyp (within three
months of diagnosis and consent) have been accrued and 1250 patients
have been randomized to one of the two arms. Patient accrual is ongoing
until Fall 1994 to achieve 950 fully evaluable patients who will undergo
the year three colonoscopy while on-study. Rectal mucosal biopsy samples
have been obtained from a 25% subset of randomized patients at baseline,
and will be repeated at one, two, and three years of follow-up for PCNA
LI and PKC isotype expression and enzyme activity. The wheat bran fiber
supplements have been well tolerated with excellent patient compliance
although non-cereal eaters have proven difficult study participants.
This Project Protocol outlines the background, significance, aims,
procedures, and progress of our Phase III wheat bran fiber trial in
patients with resected adenomatous polyps.
结直肠癌仍然是癌症死亡的第二大原因
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Samuel Alberts其他文献
David Samuel Alberts的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Samuel Alberts', 18)}}的其他基金
Cancer Prevention and Control Health Disparities Training Program
癌症预防与控制健康差异培训计划
- 批准号:
10004567 - 财政年份:2016
- 资助金额:
$ 36.57万 - 项目类别:
Cancer Prevention and Control Health Disparities Training Program
癌症预防和控制健康差异培训计划
- 批准号:
9352784 - 财政年份:2016
- 资助金额:
$ 36.57万 - 项目类别:
Cancer Prevention and Control Health Disparities Training Program
癌症预防与控制健康差异培训计划
- 批准号:
9208596 - 财政年份:2016
- 资助金额:
$ 36.57万 - 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
- 批准号:
8302390 - 财政年份:2009
- 资助金额:
$ 36.57万 - 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
- 批准号:
8533555 - 财政年份:2009
- 资助金额:
$ 36.57万 - 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
- 批准号:
8100422 - 财政年份:2009
- 资助金额:
$ 36.57万 - 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
- 批准号:
8541610 - 财政年份:2009
- 资助金额:
$ 36.57万 - 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
- 批准号:
8691078 - 财政年份:2009
- 资助金额:
$ 36.57万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Comprehensive genetic analysis-based liquid biopsy for establishment of the novel tumor biomarker in dog
基于综合遗传分析的液体活检建立狗的新型肿瘤生物标志物
- 批准号:
21K05952 - 财政年份:2021
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Towards a Virtual Biopsy: An improved multimodal imaging biomarker to guide treatment decisions in neuro-oncology by combining advanced tissue microstructure imaging with deep learning
走向虚拟活检:一种改进的多模态成像生物标志物,通过将先进的组织微观结构成像与深度学习相结合来指导神经肿瘤学的治疗决策
- 批准号:
10325327 - 财政年份:2021
- 资助金额:
$ 36.57万 - 项目类别:
Study for novel biomarker in liquid biopsy on on carcinogenic pathways induced by driver mutations
液体活检中驱动突变诱发致癌途径的新型生物标志物研究
- 批准号:
20K07671 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of liquid biopsy biomarker for precision neoadjuvant treatment for pancreatic cancer
胰腺癌精准新辅助治疗液体活检生物标志物的开发
- 批准号:
20K22861 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Novel Multiplex Biomarker Discovery Methods To Predict Breast Cancer Risk After A Benign Biopsy
良性活检后预测乳腺癌风险的新型多重生物标志物发现方法
- 批准号:
10021604 - 财政年份:2019
- 资助金额:
$ 36.57万 - 项目类别:
Biomarker screening of urothelial carcinoma using liquid biopsy
使用液体活检进行尿路上皮癌生物标志物筛查
- 批准号:
19K18575 - 财政年份:2019
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Clinical significance of liquid biopsy using a novel biomarker for sarcoma
使用新型肉瘤生物标志物进行液体活检的临床意义
- 批准号:
19K09650 - 财政年份:2019
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The search of biomarker for the liquid-biopsy to diagnose the cellular infiltration in the kidney injury
液体活检诊断肾损伤细胞浸润生物标志物的探索
- 批准号:
18K05996 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of kidney cancer biomarker for therapeutic efficacy by using imaging and liquid biopsy
利用成像和液体活检开发肾癌生物标志物以提高治疗效果
- 批准号:
18K16719 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
New biomarker for recurrence of HCC by using liquid biopsy
通过液体活检发现 HCC 复发的新生物标志物
- 批准号:
17K10678 - 财政年份:2017
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)